RxDoctor Payments Data

Sandra Chapman

Adult Health · South Euclid, OHNPI 1306950258

Payments from drug & device makers

$2,372in general payments, 2019–2025

Across 61 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$236
  • GSK$174
  • E.r. Squibb & Sons, L.L.C.$129
  • Lilly USA, LLC$109
  • Novo Nordisk$108
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$2,372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,372 in reported general payments places this provider in the 80th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$14,353
Medicare patients
40
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$123,786
TrulicityDulaglutide73$86,382
FarxigaDapagliflozin Propanediol36$45,075
OzempicSemaglutide32$32,853
JardianceEmpagliflozin33$28,471
EliquisApixaban11$15,887
TradjentaLinagliptin17$11,750
DuleraMometasone/Formoterol13$5,547
Atorvastatin Calcium220$2,471
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,204
Gabapentin147$2,137
Clindamycin Phosphate31$2,058
Albuterol Sulfate HfaAlbuterol Sulfate69$1,949
Fluocinonide20$1,644
Fluticasone Propionate100$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$109$210,168163 claims
AstraZenecaFarxiga$1,383$45,07536 claims
Novo NordiskOzempic$108$32,85332 claims
PfizerEliquis$14$15,88711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,184 adult health providers in Ohio.

Other adult health in South Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →